This invention relates to SARS-CoV-2 viruses adapted with nanoluciferase reporter molecules and mouse-adapted SARS-CoV-2 viruses, compositions including the same and methods of use thereof.

African swine fever virus (ASFV) is the etiological agent of a contagious, often lethal viral disease of domestic pigs. The control of African Swine Fever (ASF) has been hampered by the unavailability of vaccines. Experimental vaccines have been derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFVs; however, these vaccines are only successful when protecting against homologous viruses. We have constructed a recombinant Δ9GL/ΔUK virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate by deleting the specific virulence-associated 9GL (B119L) and the UK (DP96R) genes. In vivo, ASFV-G Δ9GL/ΔUK administered intramuscularly to swine even at relatively high doses (10.sup.6 HAD.sub.50) does not induce disease. Importantly, animals infected with 10.sup.4 or 10.sup.6 HAD.sub.50 are solidly protected against the presentation of clinical disease when challenged at 28 days post infection with the virulent parental strain Georgia 2007.

The present invention provides an anti-HPV E7 protein monoclonal antibody and the use thereof. The antibody can detect the HPV16 E7 protein with high specificity and recognize the HPV18 E7 protein, thereby it can distinguish between the cancerous cervical epithelial cells and the cervical abnormal or non-cancerous cervical epithelial cells.

Provided is an inspection kit that proper inspection can be performed even if a tester drips a remainder of sample. The inspection kit includes: a reagent device having a sample-dripping part, the reagent device being capable of making a sample dripped on the sample-dripping part flow in a first direction from an upstream side toward a downstream side; and a case surrounding the reagent device. A liquid-absorbing part is provided with a portion near the sample-dripping part of the case, the liquid-absorbing part guiding, according to capillary action, the remainder of the sample in a second direction differing from the first direction.

Isolated monoclonal antibodies and antigen binding fragments thereof that specifically bind neuraminidase (NA) of an N1 subtype influenza virus are disclosed herein. These antibodies and antigen binding fragments can be used for the detection of an N1 subtype influenza virus and for determining the immunogenicity of vaccines. The antibodies and antigen binding fragments also can be used for the treatment of a subject to prevent or ameliorate an influenza infection.

The present disclosure provides compositions and methods for the treatment of viral hemorrhagic fever. The compositions and methods are useful for treating hemorrhagic fever virus infections and conditions associated with such infections.

The present invention relates to a kit for detecting a virus, a composition for detecting a virus and a method for detecting a virus. According to the present invention, a kit which is capable of detecting viruses with high efficiency at low cost within a short period of time, and exhibits enhanced sensitivity and accuracy may be provided.

Biological assay systems, methods, and devices for detecting the presence of the virus responsible for COVID-19 (sars-cov-2) in the saliva of an individual. The systems, methods, and devices utilize immunoassay technology for detecting the presence of antigen in a sample, such as the virus responsible for COVID-19 in the saliva of an individual. The immunoassay technology in accordance with embodiments of the systems, methods, and devices use nano-carbon, or carbon nanoparticles attached to biorecognition/detector molecules, such as antibodies.

The present invention relates generally to an assay for detecting and differentiating multiple analytes, if present, in a single fluid sample, including devices and methods therefore.

The disclosure provides rabbit monoclonal antibodies against the spike S1 protein of SARS-CoV-2 and uses thereof. The antibody comprises: a V.sub.H CDR1 selected from the group consisting of SEQ ID NO: 1-7; a V.sub.H CDR2 selected from the group consisting SEQ ID NO: 8-14; a V.sub.H CDR3 selected from the group consisting of SEQ ID NO: 15-21; a V.sub.L CDR1 selected from the group consisting SEQ IDN NO: 22-28; a V.sub.L CDR2 selected from the group consisting of SEQ ID NO: 29-35; and a V.sub.L CDR3 selected from the group consisting of SEQ ID NO: 36-42. The antibodies can be used for a rapid test or screening of SARS-CoV-2 infection. The antibodies can also be used for treating SARS-CoV-2 infection.